anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To produce an easily absorbable vitamin K2 agent for oral administration, by dissolving vitamin K2 in a specific triglyceride or its mixture. CONSTITUTION:The objective agent can be produced by dissolving vitamin K2 in a mixture of one or more triglycerides wherein the carbon number of each constituent fatty acid group is 16-18 (e.g. triolein). Vitamin K2 is effective to activate the hemostatic mechanism i the body and is used for the remedy of hemorrhage and hypoprothrombinemia, however, it has poor absorbability by oral administration and accordingly it is administered usually by intravenous injection or intramuscular injection. The drug preparation dissolved in the above triglyceride gives high drug concentration in blood by oral administration, and is rated as a peroral drug having excellent absorbability. Since the triglyceride has low toxicity, the vitamin K2 peroral drug of the present invention has also low toxicity and can be used safely for the prevention and remedy of hemorrhage and hypoprothrombinemia.
1,220,114. Laminating with synthetic resin interlayer. CESKOSLOVENSKA AKADEMIE VED. 29 April, 1968 [12 May, 1967], No. 20171/68. Heading B5N. A hydrophilic polymer or copolymer of glycol methacrylate or acrylate is bonded to a hydrophobic layer by creating one or more intermediate layers between the hydrophilic and hydrophobic polymers, the hydrophilic properties of the intermediate layer(s) decreasing gradually or stepwise from the hydrophilic to the hydrophobic polymer. The intermediate layer can be formed first and the two articles to be bonded together are then glued on e.g. by polymerizing monomers between them and the intermediate layer, or by adding further intermediate layers with different hydrophilic properties, or by a suitable adhesive e.g. an epoxy resin for metal. The intermediate layer can be formed by gradually applying layers on to each other; or by controlled diffusion of the monomer forming the hydrophobic (hydrophilic) component or of a mixture of such monomers into the hydrophilic (hydrophobic) polymer and polymerizing the diffused monomer e.g. by heating, ionizing radiation or chemically. Specific embodiments relate to the bonding of polyglycol methacrylate/acrylate to polymethyl methacrylate, polystyrene, epoxide resins, metals. In the examples: (1) a copolymer of ethylene glycol monomethacrylate and ethyl methacrylate was cast into a layer on a horizontal glass plate. On to this layer a foil of crosslinked polyglycol methacrylate was formed by polymerizing a mixture of glycol methacrylate, glycerol and di-isopropyl percarbonate. The double layer product was removed from a glass plate and the copolymer layer joined with a polymethyl methacrylate article by means of methyl methacrylate monomer polymerized .therebetween; (2) on to a polyglycol methacrylate foil provided on both sides with intermediate copolymer layers as in (1), there were glued blocks of polymethyl methacrylate by means of a viscous solution of polymethyl methacrylate; (4) a solution of a block copolymer of ethylene glycol monomethacrylate and epoxide resin was cast into a layer on a glass plate and a polyglycol methacrylate layer formed on the copolymer as in (1). The double layer product was swelled in water and removed from the glass plate, dried and glued to a roughened and degreased copper sheet.
Procedure: Anterior Cervical Discectomy and Fusion. The treatment arm will receive 40 mg of Methylprednisolone Acetate delivered with a Hemostatic Matrix Kit prior to closure.
PURPOSE: A method for preparing a rhein derivative from sennoside A is provided to enhance anticancer effect by apoptosis and use as an anticancer drug. CONSTITUTION: A method for preparing a rhein derivative from sennoside having enhanced anticancer effect comprises: a step of adding radical generating agent to a solution containing sennoside A; and a step of irradiating radiation to the solution. The solution containing sennoside A is a solution in which sennoside A is dissolved or plant-pulverized liquid and extract containing the sennoside A as a main ingredient. The radical generating agent is hydrogen peroxide, acetyl hydroperoxide or ascorbic acid. The radiation is gamma ray, electronic beam, UV or X ray. A pharmaceutical composition for preventing and treating cancer contains the rhein derivative as an active ingredient.
All patients will be scheduled to a propofol-remifentanil general anesthesia and receive non-steroid anti-inflammatory drug before incision. Bolus sufentanil will be administered according to the blood pressure, heart rate and bispectral index perioperatively. Patients unable to understand the study procedure or unable to give informed consent, with concurrent analgesic or sedative medication, with history of chronic pain, psychiatric disorders, or alcohol or drug abuse, with an allergy to the study medication, who are pregnant or breast feeding, with a BMI \>30 and \<18 kg/m2, with severe cardiac, pulmonary, hepatic or renal dysfunction, with intracranial hypertension will be excluded.

Subjects will be randomly assigned to one of three groups: the placebo group, the low-dose S-ketamine group, and the high-dose S-ketamine group. The study medication will be administered in a bolus injected over 30 s after induction, followed by continuous infusion, which started after the initial bolus. The placebo group will receive a bolus of 0.9% saline, followed by continuous infusion of 0.9% saline. The low-dose ketamine group will be administered a bolus of 0.5 mg/kg S-ketamine in saline, followed by 2μg/kg/min S-ketamine in saline, whereas the high-dose ketamine group will be administered a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 4μg/kg/min S-ketamine in saline. The syringes and infusions will be identical for all of the groups and will run at the same rate in all subjects to enable blinding of the investigators. Study medication will be terminated 30 min prior to the end of the surgery. After surgery and in the postanesthesia care unit, patients will be asked about their pain level on a numeric rating scale (NRS), and about the presence of intraoperative awareness, nausea, vomiting, and hallucinations. Rescue analgesia of sufentanil will be provided when NRS ≥ 4 or patients require. Pain level will also be assessed at 0.5, 2, 4, 6, 12 and 24 hour postoperatively as well as 3 and 6 month after the surgery. Depression scale will be evaluated before the surgery and in the 7th postoperative day.
A zinc depot for animals may be established through the introduction of a zinc substance exhibiting slow-release characteristics for the physiology of the animal, preferably via a non-digestive route. A fluid or paste-like composition, or a bolus, may be introduced through preferred routes such as into the bloodstream, intramuscularly, or subcutaneously. Preferred zinc substances include zinc organic salts and a specified range of preferred zinc inorganic compounds. Most exhibit a low aqueous solubility, less than or equal to 0.01 g/ml of H2O at 35 °C. Other agents may enhance the effectiveness of the zinc substance, preferred agents including calcium, magnesium or selenium containing compounds or minerals, fatty acids, vegetable oils, and/or sulphur or sulphide compounds. The provision of a lasting zinc depot in an animal is useful for addressing zinc responsive disorders, both in a preventative and remedial sense. Examples of zinc-responsive disorders include facial eczema, fading elk's disease, mycotoxin poisoning, poisoning from alkaloid substances, disorders relating to phyto-oestrogen levels, and zinc deficiencies.
BACKGROUND AND PURPOSE: The association between Guillain-Barré syndrome (GBS) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is debated. This study reappraises, after three pandemic years, the epidemiological data and the features of GBS in SARS-CoV-2 patients.
METHODS: A systematic review and meta-analysis of case reports/series and cohort studies published between 1 January 2020 and 19 April 2023 was performed.
RESULTS: In all, 209 case reports/series (304 patients) and 26 cohort studies were included. The risk of GBS in northern Italy during the first pandemic wave was 2.85 times increased (95% confidence interval [CI] 1.54; 5.25) whereas in some countries the risk during the first pandemic year was 0.17 times reduced (risk ratio 0.83, 95% CI 0.75; 0.93). The incidence of GBS in SARS-CoV-2 Italian hospitalized cohorts was 8.55 per 1000 (95% CI 5.33; 12.49) with an estimated incidence of 0.13 GBS per 1000 in the SARS-CoV-2 infected population. In European cohorts the pooled rate of GBS with SARS-CoV-2 infection was 61.3% of the total. GBS patients with SARS-CoV-2 infection showed more frequently, but not differently from non-infected patients, the classical clinical presentation and the demyelinating subtype. Cranial nerves were more frequently involved in SARS-CoV-2 infected patients.
CONCLUSIONS: An increased risk of GBS occurred in northern Italy during early COVID-19 pandemic. The recognition of the 'Italian factor' reconciles contrasting results of the epidemiological studies. The slightly reduced GBS risk in other countries and the relatively high frequency of GBS associated with SARS-CoV-2 infection can be explained by the adopted health measures that decreased the circulation of other GBS infective antecedents.
BACKGROUND: Delayed cerebral ischemia represents a significant contributor to death and disability following aneurysmal subarachnoid hemorrhage. Although preclinical models have shown promising results, clinical trials have consistently failed to replicate the success of therapeutic strategies. The lack of standardized experimental setups and outcome assessments, particularly regarding secondary vasospastic/ischemic events, may be partly responsible for the translational failure. The study aims to delineate the procedural characteristics and assessment modalities of secondary vasospastic and ischemic events, serving as surrogates for clinically relevant delayed cerebral ischemia, in recent rat and murine subarachnoid hemorrhage models.
METHODS AND RESULTS: We conducted a systematic review of rat and murine in vivo subarachnoid hemorrhage studies (published: 2016-2020) using delayed cerebral ischemia/vasospasm as outcome parameters. Our analysis included 102 eligible studies. In murine studies (n=30), the endovascular perforation model was predominantly used, while rat studies primarily employed intracisternal blood injection to mimic subarachnoid hemorrhage. Particularly, the injection models exhibited considerable variation in injection volume, rate, and cerebrospinal fluid withdrawal. Peri-interventional monitoring was generally inadequately reported across all models, with body temperature and blood pressure being the most frequently documented parameters (62% and 34%, respectively). Vasospastic events were mainly assessed through microscopy of large cerebral arteries. In 90% of the rat and 86% of the murine studies, only male animals were used.
CONCLUSIONS: Our study underscores the substantial heterogeneity in procedural characteristics and outcome assessments of experimental subarachnoid hemorrhage research. To address these challenges, drafting guidelines for standardization and ensuring rigorous control of methodological and experimental quality by funders and journals are essential.
REGISTRATION: URL: https://www.crd.york.ac.uk/prospero/; Unique identifier: CRD42022337279.
Stimulate the dorsal lateral prefrontal cortex with the sham iTBS pattern and coil. The therapy will be conductedfor 30 days.
PURPOSE:To obtain the titled latex with no quality variation among lots, stable for a long period, suitable for microtiter procedure, by polymerization of styrene in the absence of emulsifier to prepare polystyrene suspension followed by crosslinking treatment thereof then chlorination treatment of the resulting polymer. CONSTITUTION:First, styrene is polymerized, normally in an aqueous medium, in the absence of emulsifier, under a weakly alkaline condition pref. at a pH 7.1-7.8 using, as an initiator, persulfate such as potassium persulfate, to prepare a polystyrene suspension. This suspension is then heat-treated pref. at a pH3- 6.8 (i.e. under a neutral or acidic condition) to prepare polystyrene particles containing crosslinked polystyrene ones, which are then subjected to chlorination treatment to obtain the objective latex. Said chlorination treatment is preferably carried out at 10-60 deg.C for 60-360min, resulting in a chlorination degree 10- 30% in weight.
The present invention relates to a diabetes treating medicine and a preparation method thereof. The diabetes treating medicine is a medicament which is prepared from traditional Chinese medicines as raw materials (portions by weight), such as 10 to 35 portions of wild balsam pear, 100 to 250 portions of kudzuvine root and 5 to 30 portions of semen litchi and both of or one kind of 1 to 100 portions of dodder and 5 to 30 portions of Chinese yam. The diabetes treating medicine has the preparation method that entirely or partly medicines are pulverized; the rest medicines are extracted by water to obtain extract; all the medicines are uniformly mixed, dried and pulverized to obtain a required preparation form. The present invention has the efficiency of quenching thirst, moistening dryness, clearing heat, promoting fluid, nourishing Yin, invigorating spleens and leveling three types of diabetes, has obviously therapeutic action and has an obvious function for reducing blood sugar. After treatment, triglyceride has a downward trend and excessive thirst, polydipsia, marasmus, adynamia, skin titillation, etc. are obviously improved. During medication, the diabetes treating medicine does not have any adverse reaction and has no side effect. Clinics and experiments show that the present invention is a safe and effective medicine for treating diabetes.
FIELD: transportation. ^ SUBSTANCE: packed product comprises the first package and substance. The first substance comprises water-permeable film that has water vapor permeability of at least 0.003 gram/100 sq. inches/24 hours at 32C and 100% of relative humidity. Substance may be placed inside the first package and may contain peroxide and water for teeth whitening. The first package may be placed inside the second package. The second package may contain regulator of water vapors. ^ EFFECT: stabilisation of peroxide concentration and increased shelf life of product. ^ 20 cl, 4 dwg, 2 tbl, 4 ex
BACKGROUND: The utilization of adjuvants such as dexamethasone and dexmedetomidine in combination with local anesthetics has proven effective in extending analgesia duration. We aimed to investigate the potential efficacy of combining dexmedetomidine and dexamethasone in rhomboid intercostal and sub-serratus (RISS) block for prolonging postoperative analgesia in patients undergoing video-assisted thoracoscopic surgery (VATS).
METHODS: We did this randomized, double-blind, controlled trial in two tertiary-care hospitals. A total of eighty-eight patients undergoing VATS under general anesthesia were enrolled in this study. They were randomly assigned into four groups: ropivacaine (R) group, ropivacaine + dexmedetomidine (RM) group, ropivacaine + dexamethasone (RS) group, or ropivacaine + dexmedetomidine + dexamethasone (RSM) group. The primary outcome measure was the duration of analgesia. Secondary outcomes included Numeric Rating Scale (NRS) scores, cumulative oxycodone consumption, and adverse effects.
RESULTS: The RSM group exhibited a significantly prolonged duration of analgesia at 1073.5 min (932.0-1283.3) compared to the R group with a duration of 154.5 min (80.5-199.3) and the RS group with a duration of 282.0 min (195.3-350.0, P < 0 0.001). The cumulative oxycodone consumption during the 0-12 hours and 0-24-hours period was significantly reduced in the RSM group compared to the R group (P < 0.05). There was also a lower incidence of nausea at 48 hours postoperatively in the RSM group compared to the RM group. However, there were no significant differences between the four groups regarding NRS pain scores.
CONCLUSION: The combination of ropivacaine, dexmedetomidine, and dexamethasone in RISS block significantly prolongs the duration of postoperative analgesia following VATS.
In a multicenter, parallel group study, 900 patients with acute lower extremity deep vein thrombosis (DVT) with or without pulmonary embolism (PE) were randomized to an inpatient (hospital) treatment of either (i) Lovenox 1.5 mg/kg once a day SC, (ii) Lovenox 1 mg/kg every 12 hours SC, or (iii) heparin IV bolus (5000 IU) followed by a continuous infusion (administered to achieve an aPTT of 55 to 85 seconds). A total of 900 patients were randomized in the study and all patients were treated. Patients ranged in age from 18 to 92 years (mean age 60.7 years) with 54.7% men and 45.3% women. All patients also received warfarin sodium (dose adjusted according to PT to achieve an International Normalization Ratio [INR] of 2.0 to 3.0), commencing within 72 hours of initiation of Lovenox or standard heparin therapy, and continuing for 90 days. Lovenox or standard heparin therapy was administered for a minimum of 5 days and until the targeted warfarin sodium INR was achieved. Both Lovenox regimens were equivalent to standard heparin therapy in reducing the risk of recurrent venous thromboembolism (DVT and/or PE). The efficacy data are provided below [see Table 21].

Similarly, in a multicenter, open-label, parallel group study, patients with acute proximal DVT were randomized to Lovenox or heparin. Patients who could not receive outpatient therapy were excluded from entering the study. Outpatient exclusion criteria included the following: inability to receive outpatient heparin therapy because of associated co-morbid conditions or potential for non-compliance and inability to attend follow-up visits as an outpatient because of geographic inaccessibility. Eligible patients could be treated in the hospital, but ONLY Lovenox patients were permitted to go home on therapy (72%). A total of 501 patients were randomized in the study and all patients were treated. Patients ranged in age from 19 to 96 years (mean age 57.8 years) with 60.5% men and 39.5% women. Patients were randomized to either Lovenox 1 mg/kg every 12 hours SC or heparin IV bolus (5000 IU) followed by a continuous infusion administered to achieve an aPTT of 60 to 85 seconds (in-patient treatment). All patients also received warfarin sodium as described in the previous study. Lovenox or standard heparin therapy was administered for a minimum of 5 days. Lovenox was equivalent to standard heparin therapy in reducing the risk of recurrent venous thromboembolism. The efficacy data are provided below [see Table 22].
The invention discloses a formula of a Hui nationality traditional Chinese medicine oyster preparation for treating liver cancer and a preparation method of the Hui nationality traditional Chinese medicine oyster preparation for treating liver cancer. The Hui nationality traditional Chinese medicine oyster preparation is an eco-friendly high-tech traditional Chinese medicine product for treating liver cancer and is a traditional Chinese medicine decoction prepared from traditional Chinese medicines such as oyster, toad, pseudobulbus cremastrae seu pleiones, rhizoma curcumae, red sage root, common yam rhizome and the like according to a certain proportion through material blending, water decoction, extraction and concentration. The Hui nationality traditional Chinese medicine oyster preparation is mainly used for treating liver cancer and also can treat digestive system cancers such as pharyngolaryngeal cancer, gastric cancer and colorectal cancer. The Hui nationality traditional Chinese medicine oyster preparation has a moderate taste and a moderate dose. The selected traditional Chinese medicines are proved to be able to treat cancers by the modern medical pharmacology experiments. The Hui nationality traditional Chinese medicine oyster preparation realizes a very low cost, can prevent and treat cell cancerization and can restore health.
### Pregnancy Category C

All pregnancies have a risk of birth defect, loss, or other adverse event regardless of drug exposure. Predictions of fetal risk from drug exposure rely heavily on animal data. However, animal studies may fail to predict effects in humans or may overstate such risks. Even if human data are available, the data may not be sufficient to determine whether there is an increased risk to the fetus, and individual reports of adverse outcomes in pregnancy in association with a drug may not reflect a causal relationship.

Lindane Shampoo should be given to pregnant women only if clearly needed. There are no adequate and well-controlled studies of Lindane Shampoo in pregnant women. There are no known maternal or fetal health risks described if lice are not treated, but risk of transmission of the lice to other household members is an additional consideration when deciding whether to use lice treatments. Lindane is lipophilic and may accumulate in the placenta. There has been a single case report of a stillborn infant following multiple maternal exposures during pregnancy to Lindane Lotion. The relationship of the maternal exposures to the fetal outcome is unknown.

Animal data suggest that lindane may increase the likelihood of neurologic developmental abnormalities (see below), based on findings at systemic exposures close to that expected in humans when Lindane Lotion is used to treat scabies. The immature central nervous system (as in the fetus) may have increased susceptibility to the effects of the drug. Systemic exposure resulting from Lindane Shampoo applied to hair covered areas is expected to be lower than that from Lindane Lotion that covers the entire body surface area.

#### Data

When rats received lindane in the diet from day 6 of gestation through day 10 of lactation, reduced pup survival, decreased pup weight and decreased weight gains during lactation, increased motor activity and decreased motor activity habituation were seen in pups at 5.6 mg/kg (2 times the estimated human exposure) but not at 1.2 mg/kg. An increased number of stillborn pups was seen at 8 mg/kg, and increased pup mortality was seen at 5.6 mg/kg. No gross abnormalities were seen in this study or in a study in which rabbits received up to 20 mg/kg lindane by gavage on gestation day 6–18 (up to 10 times the human exposure on a body surface area comparison and assuming 50% rabbit oral bioavailability and 10% human bioavailability when lindane is applied to the entire body for the treatment of scabies).
Supplements and control (MPP, WP, CON) will be consumed as a drink or in a recipe for five subsequent weeks (30 g/day); four weeks preload and one week during the Four Days Marches. With this amount, we aim to increase the protein intake from \<1.0g/kg/bw/d to \>1.2g/kg/bw/d. Participants are allowed to dissolve the powder in a liquid of choice: we will provide several examples to the participants during the instructions.
PURPOSE: To obtain a microcapsule including a natural carotenoid, having a high strength, hardly undergoing the oxidative deterioration, capable of being stably blended in a tablet etc., and useful in foods, medicines, etc. CONSTITUTION: This microcapsule is prepared by emulsifying an oily phase to be a core material in an aqueous phase which is a film-forming component, forming an O/W type emulsion having 0.001-5μm average oil droplet diameter, then dispersing the resultant emulsion in food oils and fats, cooling and solidifying the dispersed microcapsule casing and forming the microcapsule. The core material in the microcapsule comprises a natural carotenoid (e.g. palm oil carotenoid), food oils and fats (e.g. corn oil), an antioxidant, etc., and the film-forming component contains gelatin, an antioxidant, a stabilizer, sugars, etc. When a gelatin having >=250 Bloom jelly strength is used, the capsule strength is raised. The weight ratio of the palm oil carotenoid to the food oils and fats used is (20:80)-(50:50).  The microcapsule is formed into tablets having 50-3000μm average grain diameter by using an excipient.